What's new

Take Action to Preserve Access to Avastin
Apr 16, 2015    Advocacy & Practice Updates
Farewell SGR: Congress Sends SGR Repeal Bill to the President
Apr 15, 2015    Advocacy & Practice Updates
FDA OKs Eylea to Treat Diabetic Retinopathy in DME Patients
Mar 25, 2015    Industry News
ASRS Urges Horizon Blue Cross Blue Shield of NJ to Fix Eylea Claims Processing
Mar 19, 2015    Advocacy & Practice Updates
FDA Approves DORC EVA Surgical System
Mar 17, 2015    Industry News
CMS to Toughen Enforcement of MA Network Adequacy Rules
Feb 20, 2015    Advocacy & Practice Updates
Discussing Protocol T With DRCR.net Chair Lee Jampol, MD
Feb 24, 2015    Clinical Trials
FDA OKs Lucentis for Diabetic Retinopathy in DME Patients
Feb 6, 2015    Industry News
ASRS Continues Fighting Humana’s Step Therapy Policy
Feb 11, 2015    Advocacy & Practice Updates
ASRS Launches Meaningful Use FAQ
Jan 28, 2015    Advocacy & Practice Updates
Updated 2015 Medicare Physician Fee Schedule Further Cuts Retina Procedure Payments
Jan 27, 2015    Advocacy & Practice Updates
UHC Now Requiring Referrals Under AARP MedicareChoice HMO/POS Plans
Jan 14, 2015    Advocacy & Practice Updates
Health Canada Approves Argus II Retinal Prosthesis
Jan 13, 2015    Industry News
FDA Grants Breakthrough Therapy Designation to Lucentis for Diabetic Retinopathy
Dec 17, 2014    Industry News
Payers Continue Attempts to Restrict Lucentis and Eylea
Dec 17, 2014    Advocacy & Practice Updates

Retina Times

Summer 2015, Vol. 33, No. 2, Issue 59

In this issue:

From the Editor's Desk
Stop the FDA’s Proposed ‘Avastin Prohibition Act’
Who’s Flying the Plane?

From the President
‘It’s the Science …’


What’s News
What to See and Do in Vienna

The KOL Corner
Diabetic Macular Edema: Exploring the Newest Treatment Algorithms

Summer 2015 Retina Times >>


ASRS 33rd Annual Meeting
July 11-14, 2015
Vienna, Austria